GPC3 and cancer: In GPC3-positive cancer cells, two humanized anti-GPC3 antibody-drug conjugates (hYP7 and hYP9.1b) in the IgG format have been shown to cause complement-dependent cytotoxicity as well as antibody-dependent cell-mediated cytotoxicity (ADCC) [2].